CLLS · Cellectis ADR
United States · RS rating 7 · As of 2026-11-03
| Price | 1.09 USD |
|---|---|
| 1-day change | +5.3% |
| RS rating (overall / 1M / 3M / 12M) | 7 / 19 / 6 / 13 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 21 / 6 / 35 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +30.8% |
| Sales growth Q/Q | -70.4% |
| Distance from 52-week high | +79.6% |
| Market cap (USD) | $393.3M |